Distinct Pathological Pathways in Patients With Heart Failure and Diabetes
- 1 March 2020
- journal article
- research article
- Published by Elsevier in JACC: Heart Failure
- Vol. 8 (3) , 234-242
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Medtronic
- Amgen
- Boehringer Ingelheim
- Pfizer
- Merck Sharp and Dohme United Kingdom
- Roche
- GlaxoSmithKline
- European Commission (EudraCT 2010-020808-29, FP7-242209-BIOSTAT-CHF)
- Johnson and Johnson
- Biotronik
- Merck
- Servier
- Novartis
- Abbott Vascular
- Bayer
- Cytokinetics
- AstraZeneca
This publication has 41 references indexed in Scilit:
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- Activation of EGFR/ERBB2 via Pathways Involving ERK1/2, P38 MAPK, AKT and FOXO Enhances Recovery of Diabetic Hearts from Ischemia-Reperfusion InjuryPLOS ONE, 2012
- Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- The IntAct molecular interaction database in 2012Nucleic Acids Research, 2011
- Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndromeHeart Failure Reviews, 2011
- Measuring the physical cohesiveness of proteins using physical interaction enrichmentBioinformatics, 2010
- BioGRID: a general repository for interaction datasetsNucleic Acids Research, 2006
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in HumansGenome Research, 2003
- BIND: the Biomolecular Interaction Network DatabaseNucleic Acids Research, 2003